LITH (BioELife) EV-to-EBIT: 0.00 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioELife EV-to-EBIT?

BioELife LITH -99.00% EV-to-EBIT is 0.00 as of Jul. 16, 2026.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BioELife's Enterprise Value is $0.00 Mil. BioELife's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 was $-0.57 Mil. Therefore, BioELife's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for BioELife's EV-to-EBIT or its related term are showing as below:

LITH's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 15.86
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. BioELife's Enterprise Value for the quarter that ended in Sep. 2019 was $1.01 Mil. BioELife's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 was $-0.57 Mil. BioELife's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2019 was -56.00%.

BioELife  (OTCPK:LITH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BioELife's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2019 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2019 ) =EBIT / Enterprise Value (Q: Sep. 2019 )
=-0.568/1.0142
=-56.00 %

BioELife's Enterprise Value for the quarter that ended in Sep. 2019 was $1.01 Mil.
BioELife's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioELife EV-to-EBIT Related Terms

BioELife EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for BioELife's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioELife EV-to-EBIT Chart

BioELife Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.87 -17.12 -37.83 -26.22 -3.29

BioELife Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.62 -3.29 -5.57 -2.42 -1.79

LITH vs BSPK, PCYN, CNABQ: EV-to-EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioELife's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioELife EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioELife's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioELife's EV-to-EBIT falls into.


BioELife EV-to-EBIT Calculation

BioELife's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-0.568
=0.00

BioELife's current Enterprise Value is $0.00 Mil.
BioELife's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of 0.00 mean?
BioELife (LITH) has a EV-to-EBIT of 0.00 as of Jul. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BioELife and its competitors.
Is BioELife's EV-to-EBIT too high?
BioELife's current EV-to-EBIT is 0.00.
How does BioELife's EV-to-EBIT compare to BSPK and PCYN?
BioELife's EV-to-EBIT of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBIT is 15.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.86, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BioELife and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioELife's current EV-to-EBIT is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioELife stock overvalued right now?
BioELife (LITH) has a current EV-to-EBIT of 0.00. The current EV-to-EBIT is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For BioELife (LITH), the current EV-to-EBIT is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioELife Business Description

Address 12340 Seal Beach Boulevard, Suite B-190, Seal Beach, CA, USA, 90740
BioELife Corp is engaged in the manufacturing and distribution of Cannabinoid products. The company's product portfolio includes Combo Adult Gummies with Chirorub; Combo Tincture with Chirorub; Intensive Relief Rub; Tinctures; Adult Gummies; Premium Pre-Rolls; and Flower.